Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It had been raining for some time, the climber lost his footing and slipped suddenly a few feet. He gasped. But then he felt the sudden jolt on the harness as the rope pulled tight. It held; he was OK.
I must admit that when I initially saw the RNS yesterday my heart sank. Much of any investment decision should be based on a sound knowledge, conviction and trust in the management team and especially the CEO. And here was our GM suddenly being replaced by someone we didn't know from Adam.
To me GM made a couple of very strong decisions:
1. He was quick to react at a time of year when everyone else was thinking of downing tools and partying. Being first to market was key and his rapid action set us up well for 2020. This showed a level of foresight, nimbleness and hunger much lacking in some.
2. He was quick to use the cash to purchase IT-IS. This masterstroke allowed vertical integration at a very competitive rate and showed great strategic thinking. Further foresight was also shown with the bulk purchase of reagents and outsourcing of manufacturing which enabled rapid up-scaling, whilst minimising risk and capital outlay.
I was also impressed with the early vision and determination to take the company to midcap level. Hence my initial shock and disappointment when we're only half way there.
However, having had some time to reflect and do a little research on the new man, I am feeling far more positive. He looks like a sound communicator and his marketing experience will be key to the next stage of the company's development. We have so many fine products, but that's no good if they are not flying off the shelves. Novacyt needs to go global and the USA in particular has been a hard nut to crack . Other members of the new team add further experienced and will also be critical in this respect.
Like others on this board, I was also fearful of traders taking advantage of the shock news to add further selling pressure yesterday morning. The fact that this has not transpired reassures me that we have finally bottomed out at 325 with no one else prepared to sell at this rock bottom SP. I too was initially disappointed at no update, but then again, I agree with others that June figures will add little that we don't already know. It is Q3 where we will, hopefully, see the uptick.
So, back to being sanguine and looking forward to all the new developments as they arise. I'm still convinced we are well on the way to being a multibillion, multinational company. Keep hold of your golden tickets.
The rain cleared, and as he regained his footing, the intrepid climber looked up once more towards the huge climb ahead.
GLA
VERY positive moving forward here
A new driver who will be incentivised to see the SP climb, very high chance of a move to Nasdaq and building from a base of X 1.7 PE Ratio.
X 1.7 its farcical
https://www.hl.co.uk/shares/shares-search-results/n/novacyt-eur0.0667-cdi
Yes please, shorter's do what you like i'm still adding. £ 233 mcap on a business of this magnitude, world wide network, world class bioinformatics and R&D and north of £ 100m cash at bank for acquisitions.
£ 233m yes right...
Would not be surprised if this closed up today...
GLA
Rare pharma is on trend... look at AZN purchasing Alexion... could be a longer term strategy of over of the giants to acquire the newly merged Amryt/ NCYT in one go
And if we thought our volume was low.
Currency GBX
Issue Country GB
Shares in Issue 179m
Market Capitalisation £289m
Market Size 1,500
52 Week High 241.00
52 Week High Date 09-Sep-2020
52 Week Low 155.00
52 Week Low Date 04-Sep-2020
# Trades 10
Vol. Sold 1,200
Sold Value £1,932
Vol. Bought 4,550
Bought Value £7,326
PE Ratio -3.325
Earnings -48.424
Dividend 0.00
Yield 0.00%
It's an interesting thought Kitzie.
Bizarrely, Amryt Pharma have a bigger MC than us at the moment which is a bit odd given their revenue of £183m for the last year and the fact that they have a cumulative loss over the past five years of over £225m.
In fact their accounts are not pretty.
anyone think that a merger might be at play here to get onto Nasdaq.....obviously shareholders would have to agree on it first.
https://www.youtube.com/watch?v=ADcZzV9TyA0
For those that missed the earlier post, listen to David Allmond speak.
"I'm a through and through marketeer, sales, market access guy...."
"Grass roots in the commercial arena since I was first in sales and now in more global roles"
This guy is clearly experienced with Business listed on the NASDAQ. I really do hope he moves Novacyt onto the NASDAQ. This is where we need to be.
Bigger investors reach and properly rated in line with our peers. I hope this is one of his first moves – we can but hope….
At least I now understand why no new bonus package for GM was negotiated after the end of 2020. Clearly the board knew GMs intentions and were looking for a replacement CEO.
Now previously GM had an LTIP bonus deal because of some issue around alleged options and the bourse but maybe GM knew he was only doing another three years before retiring and this was going to act as his pay off?
Anyhow, David will need to be renumerated properly. I am hoping he gets granted some share options but if its another LTIP deal either way he will have a financially vested interest in the SP doing well and moving north.
As such if I was David, I would 100% move this onto the Nasdaq. We might find a decision comes in this regard sooner than we think. As such it would give us a really good boost imo. Time will tell.
I can only wish David the best of success. He joins the business at an exciting time for forward expansion.
As shareholders let’s get behind him and give the guy all the support we can muster.
Onwards and upwards
Pork’s